Deferiprone (Ferriprox)

From - A Hematology Oncology Wiki
Jump to: navigation, search

FDA approved 10/14/2011

General information

Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has higher binding affinity for iron than other metals such as copper, aluminum, and zinc.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information


  1. 1.0 1.1 1.2 Deferiprone (Ferriprox) package insert
  2. Deferiprone (Ferriprox) package insert (locally hosted backup)
  3. Ferriprox manufacturer's website
  4. Deferiprone (Ferriprox) patient drug information (UpToDate)